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Inﬂammatory rheumatic diseases have a long-lasting effect on pa-
tients' physical and psychological functioning, for instance, due to
disabling symptoms and unpredictable disease course. Conse-
quently, many patients show adjustment problems such as
depressed mood, which in turn can negatively inﬂuence their dis-
ease outcome. Speciﬁc biopsychosocial factors have shown to affect
this outcome. For example, daily stress, cognitive-behavioral risk
factors such as pain catastrophizing and avoidance, and resilience
factors such as optimism and social support inﬂuence the quality of
life, physical symptoms of pain and fatigue, and inﬂammatory
markers. Psychological interventions tackling these factors can have
beneﬁcial effects on physical and psychological functioning. Recent
advances in screening for patients at risk, tailored treatment, and
eHealth further broaden the efﬁciency and scope of these in-
terventions while simultaneously optimizing patient empower-
ment. This chapter describes the biopsychosocial risk and resilience
factors related to disease outcome and the possible beneﬁts of psy-
chological treatment strategies in inﬂammatory rheumatic diseases.
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H. van Middendorp, A.W.M. Evers / Best Practice & Research Clinical Rheumatology xxx (2016) 1e142Strong evidence has demonstrated the substantial negative impact of inﬂammatory rheumatic
diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis on everyday
quality of life. Similarly, it has beenwell-documented that the manner in which patients deal with this
chronic stressor affects their long-term physical and psychological functioning, indicating a number of
biopsychosocial risk and resilience factors in these patient groups [1e7]. Tackling these biopsychosocial
risk and resilience factors through psychological interventions has shown to have possible beneﬁts for
patients with inﬂammatory rheumatic diseases, with recent advances concerning screening, stepped
care, tailoring, and eHealth providing new opportunities for optimizing patient care [2,3,8].
In this chapter, we describe the psychological burden reported by patients with inﬂammatory
rheumatic diseases and the risk and resilience factors related to the quality of life (including physical
and psychological functioning) and disease outcome according to prospective and experimental
studies in inﬂammatory rheumatic diseases. In addition, we describe the effects of psychological in-
terventions tackling these factors and outline implications for optimizing patient care in the future
including recent advances of screening, stepped care, tailored treatment, and eHealth. Although this
review aims to capture various inﬂammatory rheumatic diseases, it is relevant to mention that most of
the studies have been performed in patients with rheumatoid arthritis. Therefore, although studies
have shown that quality-of-life impairment and biopsychosocial risk and resilience factors are mostly
comparable between diseases [9,10], generalizing the ﬁndings to all inﬂammatory rheumatic condi-
tions should be performed with caution. In addition, we use evidence from healthy controls and pa-
tients with other chronic somatic conditions in the case of a lack of studies for inﬂammatory rheumatic
diseases.Psychological burden of inﬂammatory rheumatic diseases
Inﬂammatory rheumatic diseases such as rheumatoid arthritis and ankylosing spondylitis have a
major and long-lasting effect on the quality of life of patients. Their chronic and progressive nature,
accompanied by disabling symptoms of pain, stiffness, and fatigue; their need for long-term medi-
cation use with potential serious side effects; and their unpredictable disease course lead to patients
requiring to adjust to functional disability, to limitations on almost all areas of daily life (such as work,
leisure activities, and social and family life), and to a changed and uncertain future perspective
[1e7,11e13]. In addition to the effect of the disease on daily life, the pathophysiological disease process
itself, with chronic inﬂammatory activity, may further inﬂuence psychological functioning, for
example, due to a direct link between inﬂammatory processes and depressive symptoms [2,8,14e16].
The level of psychological burden, which can vary from a mild to moderate level of psychological
distress to clinical depression and anxiety, differs between diagnostic groups and individual patients
and can vary over time [8]. The past decades have shown large improvements in disease activity control
of inﬂammatory rheumatic diseases, as shown by the large decreases in the levels of physical disability,
anxiety, and depression [17]. However, the quality of life of patients with inﬂammatory rheumatic
diseases remains considerably lower than that in the general population [13] and is comparable to that
in other chronic somatic diseases including cardiovascular conditions and diabetes [1]. Thus, many
patients show some level of heightened psychological distress, with a substantial percentage devel-
oping clinically relevant levels of distress, such as depression and anxiety, with prevalence rates
varying between 10% and 40% depending on the criteria and instruments used (e.g., clinical interviews
show lower percentages than screening questionnaires) [7,8,17e19].
A high psychological burden has been shown to signiﬁcantly impair the health-related quality of life
of patients with inﬂammatory rheumatic diseases. In addition, it negatively affects disease outcomes
including physical disability, remission scores, pharmacological treatment adherence and response,
healthcare costs, and mortality [2,8,15,20e23]. Thus, trying to minimize the level of psychological
burden of patients with inﬂammatory rheumatic diseases is of high clinical relevance, and knowing the
factors inﬂuencing this burden and their effects on the quality of life and disease outcome will aid in
the development and reﬁnement of interventions for these patient groups.
To conclude, the psychological burden of inﬂammatory rheumatic diseases is substantial, which
corresponds to the percentages reported in other chronic somatic conditions, and demands seriousPlease cite this article in press as: van Middendorp H, Evers AWM, The role of psychological factors in
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consequences for impaired quality of life and disease outcome.Risk and resilience factors for quality of life and disease outcome in inﬂammatory rheumatic
diseases
According to the biopsychosocial models of adjustment to disease, the long-term functioning of a
person in response to an uncontrollable long-term stressor such as an inﬂammatory rheumatic disease
is determined by a combination of biological, psychological, and social factors. Within such models,
both risk factors associated with worse outcomes and resilience factors that protect an individual from
potential negative consequences are included. These models mostly consist of a combination of rela-
tively stable personality characteristics, external stressors, and social aspects and a variety of cognitive,
emotional, and behavioral risk and resilience factors, which inﬂuence the quality of life and disease
outcome [3,24,25].
The risk and resilience factors included in the biopsychosocial models as depicted in Fig. 1 could
inﬂuence the quality of life and disease outcome in inﬂammatory rheumatic diseases through different
routes of possible mediating or moderating effects. As an example of a mediating role, a person high on
neuroticism, which is a general tendency to be sensitive and experience high negative affectivity, has a
higher chance to copewith stressors in an avoidant manner, which in turnwill negatively inﬂuence the
disease outcome. A moderating effect is, for example, observed in the buffer effect of social support,
showing that stressors unfavorably affect disease activity only in the event of low levels of social
support. In contrast to irreversible stressors, relatively stable personality characteristics, and elusive
social support networks, the cognitive, emotional, and behavioral risk and resilience factors are a focus
of psychological interventions and can be changed more easily.
The impact of stressors combined with an individual's risk and resilience factors on the disease
outcome in chronic inﬂammatory diseases is at least in part explained by psychophysiological re-
sponses. Psychological factors such as stressors activate or deactivate, depending on the speciﬁc
constellation of risk and resilience factors, the stress response systems that show bidirectional re-
lationships with the immune system (Fig. 2). These stress response systems consist of the autonomicCognions
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Fig. 1. Biopsychosocial adjustment model of risk and resilience factors affecting the quality of life and disease outcome in in-
ﬂammatory rheumatic diseases.
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adrenaline and noradrenaline, and the neuroendocrine system, which includes the hypothal-
amicepituitaryeadrenal (HPA) axis that secretes cortisol, a major stress regulatory parameter. Because
both pathways are connected with the immune system, inﬂuencing these pathways through psy-
chological factors may inﬂuence disease processes in immune-mediated rheumatic diseases [23,26,27].
In research on adjustment to chronic diseases, including inﬂammatory rheumatic diseases, the
main focus has traditionally been on the risk factors for a poor disease outcome, with far less research
on resilience factors that prevent a poor outcome. However, both factors are essential to understand
the relative risk of an individual for developing problems or to understand his or her potential for
recovery [28,29]. Knowledge regarding the risk and resilience factors that inﬂuence the quality of lifeStress
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Fig. 2. Psychophysiological stress response with possible links to disease outcome [reprinted with permission from De Brouwer SJM.
Psychophysiological stress reactivity in chronic inﬂammatory diseases: Stress exposure and stress management in rheumatoid
arthritis and psoriasis (thesis). Enschede: Ipskamp; 2014]. ACh, acetylcholine; ACTH, adrenocorticotropic hormone; ANS, autonomic
nervous system; CNS, central nervous system; CRH, corticotropin-releasing hormone; EPI, epinephrine; HPA axis, hypothal-
amicepituitaryeadrenal axis; IL, interleukin; NE, norepinephrine; SAM axis, sympathoadrenal medullary axis.
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struments to identify patients at risk of poor outcome and for developing interventions tailored to
speciﬁc risk proﬁles. In the following paragraphs, we provide an overview of the most consistent ev-
idence regarding the predictive role of psychological factors on inﬂammatory rheumatic diseases, as
demonstrated in prospective and experimental studies.
Prospective studies
Within this paragraph, risk and resilience factors that have shown a predictive value for the future
physical or psychological functioning of patients with inﬂammatory rheumatic diseases in prospective
studies are summarized.
Some studies have examined the prospective role of personality characteristics in inﬂammatory
rheumatic diseases. These studies conﬁrm the disease-generic ﬁnding that high neuroticism, which is
characterized by negative affectivity and sensitivity, is a risk factor; in contrast, optimism, which is
characterized by a general expectancy for positive outcomes, and extraversion, which is the tendency
to be outgoing and energetic, are protective factors for psychological and physical quality of life
[8,28,30e33].
Stressors have been relatively and consistently found to play a role in inﬂammatory rheumatic
diseases, particularly in rheumatoid arthritis. Minor or daily stressors (for example, negative inter-
personal events) are associated with more fatigue and pain, elevated immune activity, and disease
exacerbations [2,11,15,23,27,34,35]. However, less clear are the results regarding major stressors, such
as the death of a loved one. Some studies have indicatedmajor stressors to be associated with the onset
of rheumatoid arthritis, although this has been mostly concluded from retrospective studies, whereas
other studies showed disease improvement and some studies found no associations [23,27,35]. The
paradoxical effect of major stressors being associated with disease improvement in some studies has
been proposed to be due to the effect of amajor versusminor stressor on the psychophysiological stress
system activity. For example, major, but not minor, stressors are supposed to lead to increases in
cortisol release that dampens immune activity [35].
Social factors include both the availability and quality of social support by signiﬁcant others [34].
Good quality social support has shown to protect against psychological distress and increase in physical
symptoms [2,8,23]. It has, however, also been shown that problematic, unwanted, or stressful re-
lationships lead to increased distress, higher symptom levels, and increased inﬂammatory activity in
rheumatic diseases, thus indicating that the quality of social support is particularly important
[2,11,23,34]. Regarding the social aspects within the healthcare context, a satisfactory relationship
between the care provider and patient, which, for example, consists of mutual trust and active
participation of the patient in treatment and decision making, has been shown to be an important
predictor of high patient engagement andwell-being in inﬂammatory rheumatic diseases. High patient
engagement or empowerment has been shown to be related to improved treatment adherence,
treatment satisfaction, and health-related quality of life [2].
Cognitive, emotional, and behavioral factors are believed tomediate or moderate the relationship of
personality, stressors, and social factors with the quality of life and disease outcome and are frequently
a focus of psychological interventions. Cognitive factors that have been found to be related to chronic
somatic diseases in general and inﬂammatory rheumatic diseases in particular include illness per-
ceptions, which are the ideas that patients create about their illness (e.g., disease controllability) [36],
and illness cognitions, which result from an individual's cognitive evaluation of threatening aspects
related to a disease and its consequences (e.g., helplessness and acceptance) [37]. Additional often-
studied cognitive factors related to inﬂammatory rheumatic diseases include catastrophizing, which
is the tendency to ruminate about and magnify pain, combined with a feeling of helplessness to
manage it and self-efﬁcacy, which is the conﬁdence of a person in his or her ability to handle potential
stressors [38,39]. Emotional factors encompass the general or situation-speciﬁc ways that individuals
respond emotionally to stressful events (e.g., fear of pain or emotional suppression) [40,41]. Behavioral
factors include the ways inwhich persons manage situations that they perceive as stressful or as taxing
their resources, including general coping strategies or behaviors (e.g., problem-focused coping) [42]
and pain-speciﬁc behavioral responses (e.g., avoidance) [39].Please cite this article in press as: van Middendorp H, Evers AWM, The role of psychological factors in
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passive avoidance coping have shown relatively consistent prospective associations with more severe
psychological distress and physical symptoms and with a larger disease impact on daily life
[2,8,11,22,35,43e49]. Some evidence in rheumatic diseases, which corresponds with evidence from
other chronic illnesses, has also indicated that speciﬁc ways of regulating emotions, including difﬁculty
in identifying and describing emotions (alexithymia) and emotional suppression, are predictive of
impaired quality of life and increased self-reported disease activity, whereas other strategies, such as
emotional expression, could be associated with improved functioning under speciﬁc circumstances
[41,50e52]. Acceptance and self-efﬁcacy have been shown to generally protect against psychological
distress and increase in physical symptoms [2,8,23]. More recently, the role of expectancies has become
a research topic of particular interest in the area of placebo effects, in which expectancies, for example,
with regard to treatment effectiveness, have been shown to be a strong predictor of subsequent out-
comes including pain. A recent large observational study in a varied chronic pain sample has shown
that the expectancies of patients predict changes in pain intensity and interference [53].
Experimental studies
Prospective evidence of associations between psychological factors and changes in disease impact
of inﬂammatory rheumatic diseases indicates potential causal relationships of risk and resilience
factors for the quality of life and disease outcome in the future. However, causality cannot be ascer-
tained as prospective associations could also be due to factors that are associated with both the risk or
resilience factor and the change in quality of life or disease impact. Although the laboratory setting is
not a natural environment, which may limit the generalizability of the ﬁndings to daily life settings,
experimental studies that manipulate a psychological factor and examine its effect on functioning
while controlling other key factors enable true causal conclusions [26]. Although not all psychological
factors can (easily) be manipulated (e.g., personality characteristics) and not much experimental
research has been conducted in patients with inﬂammatory rheumatic diseases, the following para-
graphs will provide the current knowledge base in this or related ﬁelds (e.g., pain stimulation in
healthy participants or other chronic pain populations).
Personality traits are relatively stable across time and situations, whichmakes it hard tomanipulate
them. Nevertheless, recent studies have shown that healthy participants could be trained to become
more optimistic, which decreased the amount of pain experienced in response to an experimental pain
stimulus [54] and decreased cognitive dysfunction due to pain [55].
An area in which most experimental evidence has been gathered in inﬂammatory rheumatic dis-
eases is exposure to experimental stressors, including psychosocial stressors (e.g., public speaking,
mental arithmetic), physical stressors (e.g., physical exercise, Valsalva maneuver), and physiological
stressors (e.g., hypoglycemia, infusion of corticotropin-releasing hormone). These stressors have
shown to induce stress-related SAM, HPA, and immune responses in patients with inﬂammatory
rheumatic diseases, with the strongest effects shown in response to psychosocial stressors [26,27]. In
inﬂammatory rheumatic diseases, immune responses that are similar to those in experimental stress in
healthy individuals have been found; the exceptions are a lower Natural Killer (NK) cell cytotoxicity
after stress in patients than in controls, potentially because of chronic immune activation due to the
inﬂammatory disease [26], and an increased proinﬂammatory cytokine increase in response to a
psychosocial stressor after controlling for elevated baseline levels of proinﬂammatory cytokines in
patients with rheumatoid arthritis [56]. The link between real-life psychosocial stressors and psy-
chophysiological and immune reactivity suggests a potential role of stressors in the maintenance or
exacerbation of inﬂammatory rheumatic diseases, which is in line with the prospective evidence of a
link between stressors and disease outcome [26,27].
Many studies have also focused on the role of expectancies in determining pain reports in both
healthy and clinical populations. As determined from the broad placebo and nocebo literature, ex-
pectancies regarding the effectiveness or burden (e.g., side effects) of treatments have a major inﬂu-
ence on actual treatment effects and treatment adherence. In healthy participants, it has consistently
been found that manipulating expectancies by means of verbal suggestions or conditioning (e.g.,
through visual cues repeatedly associated with a speciﬁc pain stimulus) inﬂuences the amount of painPlease cite this article in press as: van Middendorp H, Evers AWM, The role of psychological factors in
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and increasing (nocebo) pain [57e59]. Although less often studied, evidence also suggests the pain-
relieving effects of expectancy manipulations in clinical chronic pain populations [60,61].
In line with the consistent evidence of a prospective association between pain catastrophizing and
disease burden in inﬂammatory rheumatic diseases, a recent study on both patients with chronic
headache and healthy controls has shown that inducing a temporary state of catastrophizing led to
increased levels of pain intensity and unpleasantness in response to an experimental pain stimulus. In
addition, the level of change in catastrophizing was associated with the change in pain, which is
suggestive of a direct pain-enhancing mechanism [62]. Moreover, a reduction in catastrophizing led to
reductions in pain report in healthy individuals, which was found to be modulated at the supraspinal
level [63]. Finally, providing failure feedback to healthy participants, whichmay be similar to creating a
feeling of helplessness, has been shown to lead to an increase in pain reports [64].
Psychological interventions in inﬂammatory rheumatic diseases
Because of the psychological burden and impaired quality of life that many patients with inﬂam-
matory rheumatic diseases experience and the impact of biopsychosocial factors on a broad variety of
quality-of-life and disease outcome measures, psychological interventions are relevant adjuncts to
pharmacological therapies. Many psychological interventions for these patient groups have been
developed and evaluated that tackle risk and resilience factors that have shown predictive values on
patient outcomes, such as pain coping skills training, stress management training, and interventions
that include patients' partners [3,8,65e67].
Interventionswithmost consistent evidence on effectiveness in rheumatic conditions are cognitive-
behavioral interventions. These interventions are aimed at the modiﬁcation of dysfunctional thoughts
and pain-related behaviors through strategies such as cognitive restructuring, exposure, and behav-
ioral experiments. Improvements have been found in several aspects of patient functioning, including
depression and anxiety, pain and fatigue, medication adherence, and disability, although the evidence
for long-term effectiveness has not consistently been studied [3,8,65e70]. Cognitive-behavioral in-
terventions that have shown consistent small to moderate effects in patients with inﬂammatory
rheumatic diseases include coping skills training, stress management training, motivational exercise
interventions, and emotional disclosure or therapeutic writing interventions [50,71e75] in some
studies, these interventions have shown to affect psychophysiological response systems and disease-
relevant immune parameters such as proinﬂammatory cytokines [72,76,77].
A more recent category of interventions in chronic pain conditions consists of mindfulness- and
acceptance-based interventions, such as mindfulness-based stress reduction and acceptance and
commitment therapy [78]. These interventions that focus on nonreactivity, awareness, acceptance of
physical and psychological states, and psychological ﬂexibility have shown promising results in in-
ﬂammatory rheumatic diseases or mixed chronic pain samples in improving the quality of life,
decreasing pain, and decreasing perceived disease activity [79e83]. In addition, there are preliminary
possible effects found on speciﬁc markers of inﬂammation (e.g., C-reactive protein); however, these
have not been found in rheumatic diseases [82,84].
Thus, psychological interventions tackling various risk and resilience factors have generally shown
small to moderate effects in patients with inﬂammatory rheumatic diseases, with most evidence
accumulated in rheumatoid arthritis; however, the effects are relatively modest, sometimes short-
lived, and vary considerably between individuals. Consequently, we propose a personalized health-
care approach in which psychological care may be further optimized for patients with inﬂammatory
rheumatic diseases.
Psychological self-management in inﬂammatory rheumatic diseases: a stepped personalized healthcare
approach for patients at risk
Most psychological interventions for patients with inﬂammatory rheumatic diseases consist of a
standardized treatment package, including a diversity of techniques (e.g., education, self-management,
and cognitive and behavioral exercises) and modules (e.g., focused on coping with pain and physicalPlease cite this article in press as: van Middendorp H, Evers AWM, The role of psychological factors in
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most, if not all, patients. Because of large individual differences in the level of adjustment problems,
disease outcomes, and risk and resilience factors, this “one-size-ﬁts-all” idea does not provide optimal
psychological healthcare. Likewise, not all patients with the same level of psychological burden will
experience a similar need to improve their functioning, for example, because they do not prioritize that
speciﬁc aspect of functioning that is impaired [3,85]. We propose a clinically realizable stepped
healthcare approach in which the type and content of self-management support are tailored to the
individual characteristics and needs of the patient while simultaneously broadening the outreach of
psychological help in these patient groups without unrealistically increasing the costs for patients and
society (Fig. 3).
Step 1: regular screening of adjustment problems as part of standard healthcare
As previously mentioned in this chapter, the psychological burden of inﬂammatory rheumatic
diseases is relatively high, compared to percentages reported in other chronic somatic conditions, and
demands serious attention by the healthcare professionals treating these patients. Consequently, it is of
utmost relevance to include some standardized form of psychosocial screening to estimate the
adjustment problems experienced by the individual patient and his or her need for support or health
priorities. Subsequently, if substantial adjustment problems are found and patients indicate a need to
improve these, screening could be elaborated by more speciﬁcally probing into those areas of func-
tioning that appear most affected and by evaluating the presence of speciﬁc risk and resilience factors
that could be used in treatment.
Recent advances have enabled periodic automated screening of the most relevant quality-of-life
areas of patients through online screening instruments that provide the healthcare professional with
a quick overview of (changes in) patient's functioning in comparison to norm scores from the speciﬁc
patient group or healthy participants [85,86]. Results of such screenings can be easily integrated into
regular consultations through graphically attractive and easily understandable feedback options. For
example, patient functioning can be visualized in patient proﬁle charts, thus comparing a patient's
current functioning to his or her previous functioning or to relevant data from a norm group by trafﬁc
light colors, with green areas indicating no problems, orange indicating potential problems, and red
indicating adjustment problems that need serious attention. This visualization can be used in theStep 1: Screening
Stepped personalized healthcare approach
Step 1a: Regular screening 
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Step 1b: Addional diagnoscs on speciﬁc
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Fig. 3. A stepped personalized healthcare approach for patients with inﬂammatory rheumatic diseases.
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want to work on the aspects of functioning that are either orange or red, and to discuss how this could
best be approached (e.g., varying from patient education to a referral to a psychologist for individual
treatment).
For this screening, validated and reliable questionnaires that are responsive to change should be
used. Starting with a brief and generic screening on psychological burden and quality of life indicating
the presence or absence of adjustment problems, which can be ﬁlled out at home before the
consultationwith the healthcare provider, the requested additional time investment for both patients
and healthcare personnel is minimal. Only in case of adjustment problems (i.e., a substantial psy-
chological burden or quality-of-life impairment), additional diagnostics will be required to get a
better idea of the problems (e.g., using a speciﬁc depression questionnaire when emotional func-
tioning is found to be impaired) and potential underlying mechanisms (e.g., using an illness cognition
or pain coping questionnaire). Thus, through such screening, healthcare could be optimized by only
providing care to those individuals in need, without running the risk of overlooking patients who do
not clearly state their need for help during regular consultations or offering treatments to those not in
need. In addition, this offers the possibility to personalize treatment to the speciﬁc characteristics of
the individual patient. Using screening tools regularly (e.g., every 6 months) in standard care can
signiﬁcantly contribute to efﬁcient and personalized patient care [85,87].
Step 2: offering personalized treatment options
Depending on the outcome of the screening, different action plans are possible, varying from
keeping a close watch to offering information or education and referral to another healthcare pro-
fessional (e.g., nurse, medical social worker, or psychologist). For patients with mild adjustment
problems or who are recently diagnosed, patient education will probably sufﬁce [88]. In case of
moderate adjustment problems, self-management interventions could sufﬁciently improve func-
tioning by combining educationwith some cognitive-behavioral principles such as relaxation, problem
solving, and goal setting [2]. For more severe adjustment problems, different evidence-based
personalized therapist-guided treatments have become available for diverse patient groups and also
include disease-generic approaches that encompass a broad variety of treatment modules of the most
relevant areas of functioning across diseases and different cognitive-behavioral techniques and as-
signments that can be ﬂexibly applied [68,89,90]. Within such tailored treatments, the content of the
treatment (e.g., choice of modules towork on and speciﬁc topics or assignments within eachmodule) is
based on the elaborate screening in combination with the patient priorities and judgment of the
therapist.
It has been shown that patient education or self-management is sufﬁcient for patients in the early
adjustment phase of the disease or who show mild adjustment problems and also strengthens patient
empowerment [3,88], whereas more intensive treatments are most beneﬁcial for patients who show
heightened distress levels [68,85]. Likewise, there is some evidence that personalized or tailored
treatment possibly leads to stronger and longer-lasting effects than standardized treatments in addi-
tion to increased treatment motivation, adherence, and patient satisfaction and decreased attrition
rates in both mental and physical health conditions and in both face-to-face and internet-based in-
terventions [3,85,89,91e93].
Providing psychological healthcare options through eHealth has shown an enormous rise in the
past decades. Although eHealth applications of evidence-based treatments have shown to be mostly
similar to face-to-face treatments in terms of effectiveness [94e96], they offer a number of advantages
compared to face-to-face treatment options, particularly in chronic patient samples. First, it saves time
and costs for both patients and healthcare professionals, for example, with respect to travel times and
room rents. It also makes working on the treatment far more ﬂexible for both patients and therapists,
enabling both to invest time into the treatment at the time that best suits them. Furthermore, it may
decrease the thresholds for patients to accept psychological treatment for problems (partly) associated
with their physical condition and will facilitate uptake and generalization of the techniques learned in
treatment in daily life as the treatment is already conducted within the home environment of the
patient, which also increases patient empowerment. In the current technological era, most of the older
patients also consider eHealth-based screening and treatment a viable option [97,98].Please cite this article in press as: van Middendorp H, Evers AWM, The role of psychological factors in
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conditions screened for a heightened psychological burden, including trials on patients with psoriasis
and with rheumatoid arthritis, have shown positive effects on psychological and physical functioning
and on the effect of the disease on daily life, thus indicating the potential of evidence-based internet-
based psychological treatments in inﬂammatory rheumatic diseases [89,93]. Thus, offering personal-
ized treatment options through eHealth facilitates the treatment to reach a larger number of patients in
need of help without necessarily increasing healthcare costs and offers a feasible and effective platform
for personalized treatment options in inﬂammatory rheumatic diseases.
Summary
This chapter has provided an overview of three main themes concerning the role of psychological
factors in inﬂammatory rheumatic diseases. First, the psychological burden, its origins, and its conse-
quences in patients with inﬂammatory rheumatic diseases have been described, showing that many
patients experience some psychological distress and a substantial minority suffers from clinical levels of
distress. Because of this relatively high psychological burden, biopsychosocial risk and resilience factors
that are most consistently associated with the quality of life and disease outcome in inﬂammatory
rheumatic diseases are addressed by summarizing the evidence from prospective and experimental
studies. In addition to more stable or irreversible factors such as personality characteristics, stressors,
and social support, a variety of cognitive, emotional, and behavioral factors have been described that
either directly or through psychophysiological responses inﬂuence the quality of life and disease
outcome. Risk factors for impaired functioning include perceived helplessness, passive avoidance
coping, pain catastrophizing, fear of pain, and excessive worrying, whereas resilience factors include
acceptance, self-efﬁcacy, and positive expectancies. Finally, building upon the knowledge on psycho-
logical burden and risk and resilience factors, evidence for and an outlook on different treatment options
have been described. Although many psychological interventions, including cognitive-behavioral and
mindfulness- and acceptance-based treatments, have shown beneﬁcial effects in inﬂammatory rheu-
matic diseases, treatment and its reach can be optimized by integrating regular screening into standard
healthcare, leading to personalized treatment options that can be offered through eHealth.
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